XM tidak menyediakan perkhidmatan kepada penduduk Amerika Syarikat.
W
W

Walgreens


Berita

Commercial REIT FrontView valued at $488 mln as shares drop in NYSE debut

UPDATE 3-Commercial REIT FrontView valued at $488 mln as shares drop in NYSE debut Adds analyst comment in paragraph 6 By Vedant Vinayak Vichare Oct 2 (Reuters) - Shares of FrontView REIT FVR.N fell 3.9% in their debut on the New York Stock Exchange on Wednesday, valuing the commercial real estate investment trust at $487.9 million. The Dallas, Texas-based company's shares opened at $18.25, below the initial public offering price of $19 apiece.
A
S
W

CVS surgery would provide little if any relief

RPT-BREAKINGVIEWS-CVS surgery would provide little if any relief The author is a Reuters Breakingviews columnist. The opinions expressed are his own. By Robert Cyran NEW YORK, Oct 1 (Reuters Breakingviews) - It’s easier to diagnose what ails CVS Health CVS.N than it is to prescribe a cure. Multiple profit warnings from the $78 billion healthcare conglomerate have raised doubts about its strategy.
A
C
W

CVS surgery would provide little if any relief

RPT-BREAKINGVIEWS-CVS surgery would provide little if any relief The author is a Reuters Breakingviews columnist. The opinions expressed are his own. By Robert Cyran NEW YORK, Oct 1 (Reuters Breakingviews) - It’s easier to diagnose what ails CVS Health CVS.N than it is to prescribe a cure. Multiple profit warnings from the $78 billion healthcare conglomerate have raised doubts about its strategy.
A
C
W

CVS surgery would provide little if any relief

BREAKINGVIEWS-CVS surgery would provide little if any relief The author is a Reuters Breakingviews columnist. The opinions expressed are his own. By Robert Cyran NEW YORK, Oct 1 (Reuters Breakingviews) - It’s easier to diagnose what ails CVS Health CVS.N than it is to prescribe a cure. Multiple profit warnings from the $78 billion healthcare conglomerate have raised doubts about its strategy.
A
C
W

Estee Lauder to see green shoots in China demand after stimulus, Piper Sandler says

BUZZ-Estee Lauder to see green shoots in China demand after stimulus, Piper Sandler says Updates ** Shares of cosmetics maker Estee Lauder EL.N rise as much as 3.6 % a t $103.4 4 after brokerage Piper Sandler raises PT to $122 from $114 ** Sees possible near-term positive effects of stimulus measures in China o n EL * * Brokerage conveys confidence in EL's FY25 forecast as co expects a decline in China sales in H1 * * EL's stock hits its highest since July 12 ** Brokerage warns of minor pressure
W
E

Estee Lauder to see green shoots in China demand after stimulus, Piper Sandler says

BUZZ-Estee Lauder to see green shoots in China demand after stimulus, Piper Sandler says ** Shares of cosmetics maker Estee Lauder EL.N rise 1% to $100.89 premarket after brokerage Piper Sandler raises PT to $122 from $114 ** Sees possible near-term positive effects of stimulus measures in China to EL, conveys confidence in its FY25 forecast as co expects a decline in China sales in H1 ** Brokerage warns of minor pressure on Coty's COTY.N mass cosmetics demand, maintains PT at $13 ** Says recent
W
E

U.S. STOCKS Regeneron, HP Inc, Honeywell International

BUZZ-U.S. STOCKS ON THE MOVE-Regeneron, HP Inc, Honeywell International Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 The blue-chip Dow rose on Friday to hit an intraday record high and small-cap stocks outperformed after a benign inflation report cleared the way for the Federal Reserve to focus on shoring up the labor market while continuing its interest rate easing.
A
C
E
L
R
S
W
W
U
U
D
C
L

California says Exxon's recycling claims created a 'public nuisance.' What does that mean?

EXPLAINER-California says Exxon's recycling claims created a 'public nuisance.' What does that mean? By Brendan Pierson Sept 25 (Reuters) - California's lawsuit on Monday accusing Exxon XOM.N of fueling global plastic waste pollution by misleading the public about the limitations of recycling is the latest in a line of recent cases based on a centuries-old legal theory known as public nuisance.
N
P
W
C

Baltimore to take drug distributors to trial over opioids

UPDATE 1-Baltimore to take drug distributors to trial over opioids Adds comment from Cencora in paragraph 4 By Brendan Pierson Sept 16 (Reuters) - The city of Baltimore is scheduled to go to trial this week in its $11 billion lawsuit accusing drug distributors McKesson MCK.N and Cencora COR.N of fueling an epidemic of opioid addiction and overdose deaths.
T
W
M

Baltimore to take drug distributors to trial over opioids

CORRECTED-Baltimore to take drug distributors to trial over opioids Corrects headline and lead, adds paragraphs 4-5 to state that J&J settled before trial By Brendan Pierson Sept 16 (Reuters) - The city of Baltimore is scheduled to go to trial this week in its $11 billion lawsuit accusing drug distributors McKesson MCK.N and Cencora COR.N of fueling an epidemic of opioid addiction and overdose deaths.
T
W
M

Walgreens paying $106.8 million to settle US prescription billing fraud charges

UPDATE 3-Walgreens paying $106.8 million to settle US prescription billing fraud charges Adds Justice Department comment, share price, paragraphs 4, 13 By Jonathan Stempel Sept 13 (Reuters) - Walgreens Boots Alliance WBA.O agreed to pay $106.8 million to settle charges it fraudulently billed the U.S. government for prescriptions that were never dispensed, the Department of Justice said on Friday.
W

CORRECTED Walgreens paying $106.8 million to settle US prescription billing fraud charges

CORRECTED (OFFICIAL)-UPDATE 2-Walgreens paying $106.8 million to settle US prescription billing fraud charges Corrects paragraph 3 to remove discussion of Walgreens reselling prescriptions and effectively being paid twice, after U.S. Department of Justice corrects press release to remove that accusation By Jonathan Stempel Sept 13 (Reuters) - Walgreens Boots Alliance WBA.O agreed to pay $106.8 million to settle charges it fraudulently billed the U.S.
W

Walgreens agrees to pay $106.8 mln to settle US charges over prescription billing

Walgreens agrees to pay $106.8 mln to settle US charges over prescription billing Sept 13 (Reuters) - Walgreens Boots Alliance WBA.O agreed to pay $106.8 million to settle charges it billed the U.S. government for prescriptions that were never dispensed, the Department of Justice said on Friday. The Justice Department said that from 2009 to 2020, Walgreens submitted false claims for payment to Medicare, Medicaid and other federal health care programs for prescriptions it processed but which were
W

UK's Boots names Anthony Hemmerdinger as new boss

UK's Boots names Anthony Hemmerdinger as new boss LONDON, Sept 12 (Reuters) - British health and beauty retailer Boots has promoted Anthony Hemmerdinger to the managing director role, succeeding Seb James on Nov. 4, it said on Thursday. Boots UK, owned by U.S. listed Walgreens Boots Alliance WBA.O , is one of Britain's biggest retailers, trading from about 1,900 stores and employing 52,000. Hemmerdinger, a former Asda supermarket executive, has been Boots UK's retail and operations director sinc
W

Baltimore settles with Teva, Walgreens ahead of scheduled opioid trial

UPDATE 1-Baltimore settles with Teva, Walgreens ahead of scheduled opioid trial Adds comment from J&J in paragraph 6 By Brendan Pierson Sept 10 (Reuters) - Baltimore said on Tuesday that it has settled with Walgreens WBA.O over claims that the pharmacy operator fueled opioid addiction in the Maryland city, the latest in a series of settlements totaling $402.5 million ahead of a trial scheduled to begin next week.
T
W
M

Baltimore settles with Teva, Walgreens ahead of scheduled opioid trial

Baltimore settles with Teva, Walgreens ahead of scheduled opioid trial By Brendan Pierson Sept 10 (Reuters) - Baltimore said on Tuesday that it has settled with Walgreens WBA.O over claims that the pharmacy operator fueled opioid addiction in the Maryland city, the latest in a series of settlements totaling $402.5 million ahead of a trial scheduled to begin next week.
T
W
M

Jefferies cuts PT on drug distributor McKesson, raises PT on Cardinal

BUZZ-Jefferies cuts PT on drug distributor McKesson, raises PT on Cardinal ** Brokerage Jefferies cuts PT on drug distributor McKesson MCK.N to $607 from $630, while raising PT on peer Cardinal Health CAH.N to $110 from $105 ** Says despite MCK forecasting Q2 below estimates, co's reiteration of full-year forecast gives "some level of confidence" *
W
M

From Boeing to FedEx, US labor unions flex muscle

FACTBOX-From Boeing to FedEx, US labor unions flex muscle Adds details throughout By Mrinalika Roy Oct 1 (Reuters) - The first large-scale strike by dockworkers on the U.S. East and Gulf coast in nearly 50 years, blocking everything from food to automobile shipments, has highlighted again the increasing mobilization by unions in the country since last year.
B
J
S
V
W
U
A
U
W

Walgreens hit with lawsuit claiming generic cold medicine has cancer-causing chemical

Walgreens hit with lawsuit claiming generic cold medicine has cancer-causing chemical By Diana Novak Jones Sept 4 (Reuters) - Walgreens is facing a proposed class action lawsuit brought on Wednesday by customers who say they weren’t warned that the pharmacy chain’s generic version of cold medicine Mucinex contains a cancer-causing chemical. The lawsuit, filed in Chicago federal court, claims Walgreens did not label the products or otherwise warn customers that they contained benzene, a known
W

U.S. STOCKS Dyne Therapeutics, Maxeon Solar, chip stocks

BUZZ-U.S. STOCKS ON THE MOVE-Dyne Therapeutics, Maxeon Solar, chip stocks Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main indexes fell over 1% on Tuesday as investors assessed subdued factory activity data ahead of a slew of labor market reports due through the week that could influence the extent of monetary policy easing by the Federal Reserve.
B
C
C
G
I
M
N
N
R
T
W
A
U
R
U
U
U
S
T
X
I
M
M
R



Syarat

Aset Popular

Penafian: Entiti XM Group menyediakan perkhidmatan pelaksanaan sahaja dan akses ke Kemudahan Dagangan Atas Talian, yang membolehkan sesorang melihat dan/atau menggunakan kandungan yang ada di dalam atau melalui laman web, tidak bertujuan untuk mengubah atau memperluas, juga tidak mengubah atau mengembangkannya. Akses dan penggunaan tersebut tertakluk kepada: (i) Terma dan Syarat; (ii) Amaran Risiko; dan Penafian Penuh. Oleh itu, kandungan sedemikian disediakan tidak lebih dari sekadar maklumat umum. Terutamanya, perlu diketahui bahawa kandungan Kemudahan Dagangan Atas Talian bukan permintaan, atau tawaran untuk melakukan transaksi dalam pasaran kewangan. Berdagang dalam mana-mana pasaran kewangan melibatkan tahap risiko yang besar terhadap modal anda.

Semua bahan yang diterbitkan di Kemudahan Dagangan Atas Talian kami bertujuan hanya untuk tujuan pendidikan/maklumat dan tidak mengandungi – dan tidak boleh dianggap mengandungi nasihat kewangan, cukai pelaburan atau dagangan dan cadangan, atau rekod harga dagangan kami, atau tawaran, atau permintaan untuk suatu transaksi dalam sebarang instrumen kewangan atau promosi kewangan yang tidak diminta kepada anda.

Sebarang kandungan pihak ketiga serta kandungan yang disediakan oleh XM, seperti pendapat, berita, penyelidikan, analisis, harga, maklumat lain atau pautan ke laman web pihak ketiga yang terdapat dalam laman web ini disediakan berdasarkan "seadanya" sebagai ulasan pasaran umum dan bukanlah nasihat pelaburan. Sesuai dengan apa-apa kandungan yang ditafsir sebagai penyelidikan pelaburan, anda mestilah ambil perhatian dan menerima bahawa kandungan tersebut tidak bertujuan dan tidak sediakan berdasarkan keperluan undang-undang yang direka untuk mempromosikan penyelidikan pelaburan bebas dan oleh itu, ia dianggap sebagai komunikasi pemasaran di bawah peraturan dan undang-undang yang berkaitan. SIla pastikan bahawa anda telah membaca dan memahami Notifikasi mengenai Penyelidikan Pelaburan Bukan Bebas dan Amaran Risiko mengenai maklumat di atas yang boleh diakses di sini.

Amaran Risiko: Modal anda dalam risiko. Produk yang berleveraj mungkin tidak sesuai untuk semua individu. Sila pertimbangkan Pendedahan Risiko kami.